Comments

Intra-Cellular Therapies

ITCINASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$76.48
1.622.16%
At Close: -
$76.48
00.00%
After Hours: 5:08 PM EDT
15 minutes delayed
Intra-Cellular Therapies (ITCI) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesGovernment TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$120.00
Lowest Price Target1
$59.00
Consensus Price Target1
$88.69

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

Intra-Cellular Therapies (NASDAQ:ITCI) Stock, Analyst Ratings, Price Targets, Forecasts

Intra-Cellular Therapies Inc has a consensus price target of $88.69 based on the ratings of 16 analysts. The high is $120 issued by Cantor Fitzgerald on June 14, 2024. The low is $59 issued by Piper Sandler on April 22, 2022. The 3 most-recent analyst ratings were released by Needham, UBS, and RBC Capital on July 22, 2024, June 25, 2024, and June 25, 2024, respectively. With an average price target of $95.33 between Needham, UBS, and RBC Capital, there's an implied 24.65% upside for Intra-Cellular Therapies Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
3
1
Apr
0
0
0
0
May
3
1
Jun
0
0
0
0
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Needham
UBS
RBC Capital
Mizuho
Canaccord Genuity

1calculated from analyst ratings

Analyst Ratings for Intra-Cellular Therapies

Buy NowGet Alert
07/22/2024Buy Now30.75%Needham
Ami Fadia
$94 → $100MaintainsBuyGet Alert
06/25/2024Buy Now8.53%UBS
Ashwani Verma
$85 → $83DowngradeBuy → NeutralGet Alert
06/25/2024Buy Now34.68%RBC Capital
Brian Abrahams
$103 → $103ReiteratesOutperform → OutperformGet Alert
06/21/2024Buy Now30.75%Mizuho
Graig Suvannavejh
$96 → $100MaintainsBuyGet Alert
06/20/2024Buy Now47.75%Canaccord Genuity
Sumant Kulkarni
$107 → $113MaintainsBuyGet Alert
06/18/2024Buy Now22.91%Needham
Ami Fadia
$90 → $94MaintainsBuyGet Alert
06/14/2024Buy Now56.9%Cantor Fitzgerald
Charles Duncan
$120 → $120ReiteratesOverweight → OverweightGet Alert
06/12/2024Buy Now1.99%JP Morgan
Jessica Fye
$75 → $78MaintainsOverweightGet Alert
05/08/2024Buy Now17.68%Needham
Ami Fadia
 → $90ReiteratesBuy → BuyGet Alert
05/07/2024Buy Now17.68%Needham
Ami Fadia
 → $90ReiteratesBuy → BuyGet Alert
04/24/2024Buy Now56.9%Cantor Fitzgerald
Charles Duncan
 → $120ReiteratesOverweight → OverweightGet Alert
04/23/2024Buy Now39.91%Canaccord Genuity
Sumant Kulkarni
$100 → $107MaintainsBuyGet Alert
04/22/2024Buy Now17.68%Needham
Ami Fadia
$82 → $90MaintainsBuyGet Alert
04/22/2024Buy Now25.52%Mizuho
Graig Suvannavejh
$82 → $96MaintainsBuyGet Alert
04/17/2024Buy Now0.68%Goldman Sachs
Corinne Jenkins
$67 → $77MaintainsNeutralGet Alert
04/17/2024Buy Now18.99%B of A Securities
Jason Gerberry
$82 → $91MaintainsBuyGet Alert
04/17/2024Buy Now34.68%Baird
Joel Beatty
$83 → $103MaintainsOutperformGet Alert
04/17/2024Buy Now17.68%TD Cowen
Joseph Thome
$80 → $90MaintainsBuyGet Alert
04/16/2024Buy Now7.22%Needham
Ami Fadia
 → $82ReiteratesBuy → BuyGet Alert
04/05/2024Buy Now7.22%Needham
Ami Fadia
 → $82ReiteratesBuy → BuyGet Alert
04/03/2024Buy Now12.45%RBC Capital
Brian Abrahams
 → $86ReiteratesOutperform → OutperformGet Alert
02/23/2024Buy Now32.06%Cantor Fitzgerald
Charles Duncan
 → $101ReiteratesOverweight → OverweightGet Alert
02/23/2024Buy Now12.45%RBC Capital
Brian Abrahams
 → $86ReiteratesOutperform → OutperformGet Alert
02/23/2024Buy Now30.75%Canaccord Genuity
Sumant Kulkarni
$101 → $100MaintainsBuyGet Alert
02/23/2024Buy Now7.22%Needham
Ami Fadia
$72 → $82MaintainsBuyGet Alert
02/16/2024Buy Now7.22%Mizuho
Graig Suvannavejh
$76 → $82MaintainsBuyGet Alert
01/31/2024Buy Now12.45%RBC Capital
Brian Abrahams
 → $86ReiteratesOutperform → OutperformGet Alert
01/18/2024Buy Now-16.32%Goldman Sachs
Corinne Jenkins
$58 → $64MaintainsNeutralGet Alert
01/03/2024Buy Now8.53%Baird
Joel Beatty
 → $83Initiates → OutperformGet Alert
01/02/2024Buy Now7.22%B of A Securities
Ashwani Verma
$74 → $82MaintainsBuyGet Alert
12/14/2023Buy Now32.06%Cantor Fitzgerald
Charles Duncan
 → $101ReiteratesOverweight → OverweightGet Alert
12/11/2023Buy Now-1.94%TD Cowen
Joseph Thome
 → $75Initiates → OutperformGet Alert
11/03/2023Buy Now-0.63%RBC Capital
Brian Abrahams
$77 → $76MaintainsOutperformGet Alert
11/03/2023Buy Now32.06%Cantor Fitzgerald
Charles Duncan
$98 → $101MaintainsOverweightGet Alert
11/03/2023Buy Now-5.86%Needham
Ami Fadia
$71 → $72MaintainsBuyGet Alert
08/22/2023Buy Now28.14%Cantor Fitzgerald
Charles Duncan
 → $98ReiteratesOverweight → OverweightGet Alert
08/04/2023Buy Now4.6%Morgan Stanley
Jeffrey Hung
$80 → $80ReiteratesOverweight → OverweightGet Alert
08/04/2023Buy Now3.29%RBC Capital
Brian Abrahams
$78 → $79MaintainsOutperformGet Alert
08/04/2023Buy Now-5.86%Needham
Ami Fadia
$73 → $72MaintainsBuyGet Alert
08/03/2023Buy Now-4.55%Needham
Ami Fadia
 → $73Reiterates → BuyGet Alert
07/11/2023Buy Now4.6%Morgan Stanley
Jeffrey Hung
$80 → $80ReiteratesOverweight → OverweightGet Alert
07/06/2023Buy Now-4.55%Needham
Ami Fadia
$70 → $73MaintainsBuyGet Alert
06/23/2023Buy Now17.68%Cantor Fitzgerald
Charles Duncan
$90 → $90ReiteratesOverweight → OverweightGet Alert
06/22/2023Buy Now-0.63%RBC Capital
Brian Abrahams
 → $76ReiteratesOutperform → OutperformGet Alert
06/05/2023Buy Now-18.93%JP Morgan
Jessica Fye
$58 → $62MaintainsOverweightGet Alert
05/08/2023Buy Now-0.63%Mizuho
Graig Suvannavejh
$74 → $76MaintainsBuyGet Alert
05/05/2023Buy Now-0.63%RBC Capital
Brian Abrahams
$72 → $76MaintainsOutperformGet Alert
05/05/2023Buy Now17.68%Cantor Fitzgerald
Charles Duncan
$87 → $90MaintainsOverweightGet Alert
04/21/2023Buy Now4.6%Morgan Stanley
Jeffrey Hung
 → $80Reiterates → OverweightGet Alert
04/20/2023Buy Now4.6%Morgan Stanley
Jeffrey Hung
 → $80Initiates → OverweightGet Alert
04/18/2023Buy Now-13.7%Needham
Ami Fadia
 → $66MaintainsBuyGet Alert
03/30/2023Buy Now-3.24%Mizuho
Graig Suvannavejh
$66 → $74MaintainsBuyGet Alert
03/29/2023Buy Now13.76%Cantor Fitzgerald
Charles Duncan
$83 → $87MaintainsOverweightGet Alert
03/29/2023Buy Now-17.63%B of A Securities
Ashwani Verma
$62 → $63MaintainsBuyGet Alert
03/29/2023Buy Now28.14%Canaccord Genuity
Sumant Kulkarni
$93 → $98MaintainsBuyGet Alert
03/29/2023Buy Now-3.24%Mizuho
Graig Suvannavejh
$66 → $74MaintainsBuyGet Alert
03/29/2023Buy Now-13.7%Needham
Ami Fadia
 → $66Reiterates → BuyGet Alert
03/09/2023Buy Now-24.16%JP Morgan
Jessica Fye
$59 → $58MaintainsOverweightGet Alert
03/02/2023Buy Now-7.17%RBC Capital
Brian Abrahams
$75 → $71MaintainsOutperformGet Alert
03/02/2023Buy Now-13.7%Needham
Ami Fadia
$70 → $66MaintainsBuyGet Alert
03/01/2023Buy Now-8.47%Needham
Ami Fadia
 → $70Reiterates → BuyGet Alert
02/10/2023Buy Now-8.47%Needham
Ami Fadia
 → $70Reiterates → BuyGet Alert
02/01/2023Buy Now8.53%Cantor Fitzgerald
Charles Duncan
 → $83Reiterates → OverweightGet Alert
08/22/2022Buy Now-35.93%Goldman Sachs
Corinne Jenkins
$64 → $49DowngradeBuy → NeutralGet Alert
08/11/2022Buy Now-5.86%Mizuho
Graig Suvannavejh
$75 → $72MaintainsBuyGet Alert
08/10/2022Buy Now-8.47%RBC Capital
Brian Abrahams
$71 → $70MaintainsOutperformGet Alert
08/10/2022Buy Now-12.4%Needham
Ami Fadia
$65 → $67MaintainsBuyGet Alert
07/07/2022Buy Now-3.24%Mizuho
Graig Suvannavejh
 → $74Initiates → BuyGet Alert
06/14/2022Buy Now-1.94%UBS
Ashwani Verma
 → $75Initiates → BuyGet Alert
04/22/2022Buy Now-22.86%Piper Sandler
Charles Duncan
 → $59Initiates → NeutralGet Alert
04/21/2022Buy Now-8.47%SVB Leerink
Marc Goodman
$65 → $70MaintainsOutperformGet Alert
03/02/2022Buy Now-15.01%SVB Leerink
Marc Goodman
$50 → $65MaintainsOutperformGet Alert
02/25/2022Buy Now-15.01%Needham
Ami Fadia
$59 → $65MaintainsBuyGet Alert
02/16/2022Buy Now-16.32%Goldman Sachs
Corinne Jenkins
 → $64Initiates → BuyGet Alert
12/21/2021Buy Now-28.09%RBC Capital
Brian Abrahams
$50 → $55MaintainsOutperformGet Alert
12/20/2021Buy Now-22.86%Needham
Ami Fadia
—MaintainsBuyGet Alert
12/20/2021Buy Now-34.62%SVB Leerink
Marc Goodman
—MaintainsOutperformGet Alert
11/10/2021Buy Now-34.62%RBC Capital
Brian Abrahams
—MaintainsOutperformGet Alert
10/19/2021Buy Now-37.24%RBC Capital
Brian Abrahams
—MaintainsOutperformGet Alert
09/23/2021Buy Now-28.09%Needham
Ami Fadia
—Initiates → BuyGet Alert
09/20/2021Buy Now-8.47%Jefferies
Andrew Tsai
—MaintainsBuyGet Alert

FAQ

Q

What is the target price for Intra-Cellular Therapies (ITCI) stock?

A

The latest price target for Intra-Cellular Therapies (NASDAQ:ITCI) was reported by Needham on July 22, 2024. The analyst firm set a price target for $100.00 expecting ITCI to rise to within 12 months (a possible 30.75% upside). 40 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Intra-Cellular Therapies (ITCI)?

A

The latest analyst rating for Intra-Cellular Therapies (NASDAQ:ITCI) was provided by Needham, and Intra-Cellular Therapies maintained their buy rating.

Q

When was the last upgrade for Intra-Cellular Therapies (ITCI)?

A

There is no last upgrade for Intra-Cellular Therapies

Q

When was the last downgrade for Intra-Cellular Therapies (ITCI)?

A

The last downgrade for Intra-Cellular Therapies Inc happened on June 25, 2024 when UBS changed their price target from $85 to $83 for Intra-Cellular Therapies Inc.

Q

When is the next analyst rating going to be posted or updated for Intra-Cellular Therapies (ITCI)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Intra-Cellular Therapies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Intra-Cellular Therapies was filed on July 22, 2024 so you should expect the next rating to be made available sometime around July 22, 2025.

Q

Is the Analyst Rating Intra-Cellular Therapies (ITCI) correct?

A

While ratings are subjective and will change, the latest Intra-Cellular Therapies (ITCI) rating was a maintained with a price target of $94.00 to $100.00. The current price Intra-Cellular Therapies (ITCI) is trading at is $76.48, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch